Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Search results

Showing results for

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Example vaccine vial in clinic © John Cairns

PCV15 Participant Information Sheet - Southampton v5.0

PCV15_PCV20 - Participant Information Sheet V5.0_21Jan2026_clean (Localised)_soton.pdf (737 KB)

PCV15 Participant Information Sheet - Bristol v5.0

PCV15_PCV20 - Participant Information Sheet V5.0_21Jan2026_localised_bristol.pdf (574 KB)

ReSET Summary Information Sheet - Stage 1 Oxford - v1.1

ReSET - Summary Information SheetV 1.1 22 April 2026.pdf (155 KB)

ReSET Participant Information Sheet - Stage 1 Oxford - v1.2

ReSET - Participant Information Sheet (Stage 1) V1.2 07 May 2026.pdf (407 KB)

IIC 2026 Programme

IIC 2026 Programme - May Draft.pdf (972 KB)

PCV15 Participant Information Sheet - Oxford v5.0

PCV15_PCV20 - Participant Information Sheet V5.0_21Jan2026_localised.pdf (556 KB)

Immunisation Update Training Programme Tues 10 Nov 2026

Immunisation Update Training Programme Tues 10 Nov 2026

Draft Programme - Immunisation Update Tues 10 Nov 26.pdf (690 KB)

Immunisation Update Training Programme Wed 11 Nov 2026

Immunisation Update Training Programme Wed 11 Nov 2026

Draft Programme - Immunisation Update Wed 11 Nov 26.pdf (687 KB)

BiVISTA Participant Information Sheet - Cardiff - v3.1

BiVISTA_PIS_V3.1_04 Nov 2025 LOCALISED_cardiff.pdf (804 KB)

MUCOSAL Participant Information Sheet - Abbreviated - v3.0

MUCOSAL abbreviated PIS V3.0 11 February 2026.pdf (606 KB)

MUCOSAL Participant Information Sheet - Full - v3.0

MUCOSAL PIS V3.0 11 February 2026.pdf (804 KB)

BiVISTA Optum Participant Information Sheet - UCLH - v3.1

BiVISTA_PIS_V3.1_04 Nov 2025 Clean_Localised_Optum._uclhpdf.pdf (781 KB)

BiVISTA Participant Information Sheet - UCLH - v3.1

BiVISTA_PIS_V3.1_04 Nov 2025 Clean_Localised_uclh.pdf (782 KB)

BiVISTA Optum Participant Information Sheet - Sheffield - v3.1

BiVISTA_PIS_V3.1_04 Nov 2025 Clean_Sheffield_Localised Optum.pdf (806 KB)

BiVISTA Optum Participant Information Sheet - SGUL - v3.1

BiVISTA_PIS_V3.1_04 Nov 2025 Clean Optum_sgul.pdf (806 KB)

BiVISTA Participant Information Sheet - Sheffield - v3.1

BiVISTA_PIS_V3.1_04 Nov 2025 Clean_Sheffield_Localised.pdf (806 KB)

BiVISTA Participant Information Sheet - SGUL - v3.1

BiVISTA_PIS_V3.1_04 Nov 2025 Clean_sgul.pdf (800 KB)

BiVISTA Optum Participant Information Sheet - Manchester - v3.1

BiVISTA PIS V3.1 04 Nov 2025 Optum_manchester.pdf (813 KB)

BiVISTA Optum Participant Information Sheet - Southampton - v3.1

BiVISTA_PIS_V3.1_04 Nov 2025 Localised Optum_soton.pdf (828 KB)

BiVISTA Participant Information Sheet - Manchester - v3.1

BiVISTA PIS V3.1 04 Nov 2025_manchesster.pdf (813 KB)

Load More

Similar stories